
Please try another search
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Name | Age | Since | Title |
---|---|---|---|
Scott D. Myers | 57 | 2021 | Independent Chairman of the Board |
Ryan Spencer | 46 | 2019 | CEO & Director |
Daniel L. Kisner | 78 | 2010 | Independent Director |
Emilio A. Emini | 72 | 2025 | Director |
Robert L. Coffman | 78 | 2000 | Member of Scientific Advisory Board |
Stanley A. Plotkin | 92 | 2005 | Member of Scientific Advisory Board |
Francis R. Cano | 80 | 2009 | Independent Director |
E. John Wherry | - | 2018 | Member of Scientific Advisory Board |
Miriam Merad | - | 2018 | Member of Scientific Advisory Board |
Laura Q. M. Chow | - | 2018 | Member of Scientific Advisory Board |
Andrew Mark Pardoll | - | 2018 | Member of Scientific Advisory Board |
Brent MacGregor | 61 | 2020 | Independent Director |
Elaine D. Sun | 53 | 2021 | Independent Director |
Peter R. Paradiso | 74 | 2020 | Chairman of the Scientific Advisory Board & Independent Director |
Rino Rappuoli | 73 | 2023 | Member of Scientific Advisory Board |
Kathryn M. Edwards | - | 2023 | Member of Scientific Advisory Board |
Lauren P. Silvernail | 67 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review